I disagree - IMO it is a big deal as it signals a shift in focus from product development (the product being BOT) to sales - in other words now there is a company, now there are four potential products, so now the focus is on selling BOT!
My hopes:
Trial momentum will be maintained.
Posited "problem" of BTX 1503 repair inhibition will be addressed.
Fast-tracking BTX 1801 to a product will be attempted.
Melanoma only studied if resources not diverted from existing work.
Funding from big pharma without cramping Botanix' style (or worth).
I disagree - IMO it is a big deal as it signals a shift in focus...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.169M | 3.655M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 274982 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 48600 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
